Increased Risk of Subsequent Cancers in Patients With Sézary Syndrome

• by Julia Nenonen, Despoina Tsakona, Philip Curman, Hanna Brauner

• October 26, 2026

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

• by Meletios Athanasios Dimopoulos, Vania Hungria, Haitao Meng, Atanas Radinoff, Jian Li, Sosana Delimpasi, Ting Niu, Gabor Mikala, Tamas Masszi, Marcelo Capra, Michael Low, Angelo Maiolino, Yan Xu, Xavier Leleu, Vasiliki Pappa, Dominik Chraniuk, Tatiana Konstantinova, Iurii Osipov, Shawn Hakim, Chris Brawley, Gabriela Tubel, Astrid McKeown, Julia Boyle, Sumita Roy-Ghanta, Katja Weisel

• October 17, 2026

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

• by Adam D. Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P. Laubach, Sheeba K. Thomas, Simon J. Harrison, Luciano J. Costa, Andrew Spencer, Rafael Fonseca, Peter A. Forsberg, Jesus G. Berdeja, Rayan Kaedbey, Nizar J. Bahlis, Paula Rodriguez-Otero, Maria-Victoria Mateos, Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong, James Cooper, Amrita Krishnan

• October 20, 2026

Beyond Detection: How AI Is Reshaping Breast Imaging and Risk-Based Screening

Artificial intelligence in breast imaging is rapidly expanding beyond computer-aided cancer detection.

• by

• October 26, 2026

• 6 min